Business context and reporting period
Entity mismatch: The request identifies NeuroOne Medical Technologies Corp., but the supplied Form 10-Q is for Original Source Entertainment, Inc., a development-stage company planning to license songs for television and film. This summary reflects the supplied filing, not NeuroOne. The report covers the quarter and nine months ended September 30, 2013; it was signed November 14, 2013.
Financial performance and position
- Revenue: Third-quarter royalty revenue was $252, compared with $23 in the prior-year quarter. Nine-month revenue was $1,109, versus $561.
- Profitability: Third-quarter net loss was $5,131, compared with $4,780. Nine-month net loss was $27,561, compared with $12,535. Gross profit equaled revenue in the periods shown because no period cost of sales was reported; revenue remained very small relative to expenses.
- Expenses and margins: Third-quarter general and administrative expense was $4,982, up from $4,754; interest expense was $401, up from $49. Nine-month G&A was $23,619, versus $12,927, and interest expense was $1,051, plus a $4,000 beneficial-conversion-feature charge. The filing attributes the G&A increase to costs associated with the company’s DTC eligibility application and approval.
- Cash flow: Nine-month operating cash use was $22,510, with no investing cash flow. Financing provided $22,000—$9,500 from note borrowings and $12,500 from paid-in capital—leaving cash of $608 per the cash-flow statement and MD&A.
- Liquidity and debt: The balance sheet reports current liabilities of $18,355, including $17,000 of current notes payable, $952 due to related parties, and $403 accrued interest. Management states the company had a working-capital deficiency and substantial doubt about its ability to continue as a going concern.
Changes, outlook, and risks
Compared with the first nine months of 2012, revenue increased, but the net loss widened, primarily as G&A and interest costs rose. Management expects continuing losses and negative operating cash flows and says additional debt or equity financing will be needed; it cannot assure financing will be available on acceptable terms. No material capital-expenditure commitments, off-balance-sheet arrangements, contractual obligations, or legal proceedings were reported. Management reported disclosure controls effective and no material change in internal controls during the quarter.
Unusual reporting inconsistencies: The MD&A incorrectly calls the 2013 nine-month result “net income” while stating $27,561; the financial statements show a net loss of $27,561. The balance-sheet cash figure and comparative column dates also appear inconsistent with the cash-flow statement and MD&A, which identify September 30 cash as $608. The filing text does not provide a clear reconciliation.
Key facts for investors to verify
- Confirm the filing’s correct issuer: the supplied report is for Original Source Entertainment, Inc., not NeuroOne Medical Technologies Corp.
- Reconcile September 30 cash and the balance-sheet column dates against the reported $608 ending cash balance.
- Verify the $27,561 nine-month net loss and the nature and terms of the $4,000 beneficial-conversion-feature charge.
- Assess near-term financing needs, note repayment terms, and the company’s stated going-concern uncertainty.
- Evaluate whether royalty revenue can grow enough to support ongoing operating expenses.